7 publications
| Name | Date | Type | Actions |
|---|---|---|---|
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
H1 2022 Sales H1 2022 Sales: €271m, up 6.1% |
20/07/2022 | Public releases | |
2008 annual earnings The Vétoquinol Board of Directors, meeting on March 20, 2009, reviewed the group’s business and approved the group’s 2008 financial statements. |
31/03/2009 | Public releases | |
2016 sales: €350.3 million 4.3% like-for-like growth The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%. |
26/01/2017 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2011 (french version) The registration document of Vétoquinol relative to fiscal year 2011, including the annual financial report relative to fiscal year 2011, was registered with the Autorité des marchés financiers (“the AMF”) on April 20th, 2012. |
23/04/2012 | Public releases | |
Vétoquinol completes the acquisition of Wockhardt Animal Health in India August 20, 2009 (Lure, France) – Vétoquinol today announced the completion of its acquisition of the animal health business division of Wockhardt Limited, based in Mumbaï, India. This acquisition was the subject of an agreement signed with the Wockhardt Limited group on June 26. |
20/08/2009 | Public releases | |
Strong growth in 2009 Revenues: +7.6% January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions. |
20/01/2010 | Public releases |